EUVIMEDEUVIMED entdecken
Open Access

Chaperone nanomotors with chemotactic ability for the treatment of Parkinson’s disease

Wenjing Wang iD, Xue Xia, Ziqiang Zhang, Qingya Zhu, Yu Chen, Yao Zhang, Lin Chen, Chun Mao iD, Mimi Wan iD

Science Advances · 2025

DOI: 10.1126/sciadv.adw1061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Wenjing Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Microbial Technology, National and Local Joint Engineering Research Center of Biomedical Functional Materials, School of Chem…. Hauptthemen laut MEDLINE: Parkinson Disease, alpha-Synuclein, Molecular Chaperones, Chemotaxis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aggregation of α-synuclein (α-syn) represents a pathogenic hallmark of Parkinson’s disease (PD). Using exogenous molecular chaperone systems has the potential to stabilize native conformations and inhibit the aberrant aggregation of α-syn, yet inefficient blood-brain barrier (BBB) penetration and insufficient accumulation at PD sites limit their application. Herein, we developed chemotactic chaperone nanomotors (CNMs) that exploit the unique pathological microenvironment of PD lesions, characterized by elevated inducible nitric oxide synthase (iNOS) levels. The CNMs consist of a chemotactic-targeting module capable of sensing an iNOS concentration gradient, an α-syn–specific recognition module with conformation-sensitive binding domains, and a protein regulatory module with a hydrophobic microdomain that can stabilize α-syn and prevent misfolding. Results demonstrate that CNMs can achieve active chemotactic navigation across BBB and dual modulation of α-syn proteostasis through aggregate dissolution and prevention of misfolding. CNMs not only supplement exogenous chaperone activity but also restore endogenous protein stabilization mechanisms, concurrently reducing neuroinflammatory markers, promoting the application of nanochaperones for PD treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson Diseasealpha-SynucleinMolecular ChaperonesChemotaxisHumansBlood-Brain BarrierAnimalsNitric Oxide Synthase Type IIProtein FoldingMice

Substanzen

alpha-SynucleinMolecular ChaperonesNitric Oxide Synthase Type II

Autor:innen und Institutionen

  • State Key Laboratory of Microbial Technology, National and Local Joint Engineering Research Center of Biomedical Functional Materials, School of Chemistry and Materials Science, Nanjing Normal University, Nanjing 210023…

ORCID-Profile: Wenjing Wang, Chun Mao, Mimi Wan

Zitieren

APA

Wang, W., Xia, X., Zhang, Z., Zhu, Q., Chen, Y., Zhang, Y., Chen, L., Mao, C., & Wan, M. (2025). Chaperone nanomotors with chemotactic ability for the treatment of Parkinson’s disease. Science Advances. https://doi.org/10.1126/sciadv.adw1061

Vancouver

Wang W, Xia X, Zhang Z, Zhu Q, Chen Y, Zhang Y, et al. Chaperone nanomotors with chemotactic ability for the treatment of Parkinson’s disease. Science Advances. 2025. doi:10.1126/sciadv.adw1061

BibTeX
@article{Wang2025,
  author = {Wang, Wenjing and Xia, Xue and Zhang, Ziqiang and Zhu, Qingya and Chen, Yu and Zhang, Yao and Chen, Lin and Mao, Chun and Wan, Mimi},
  title = {Chaperone nanomotors with chemotactic ability for the treatment of Parkinson’s disease},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.adw1061}
}
Kostenlos starten →